Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052310 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
A Phase 3 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,043
- Enrollment target
NCT02052310 is a Phase 3 study that has completed, run by Kyntra Bio. The registered enrollment target is 1,043 participants.
The verdict
NCT02052310, a Phase 3 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,043 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.
Interventions
- DRUG Epoetin Alfa
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2014-02-11 |
| Est. Completion | 2018-09-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052310
The ClinicalTrials.gov registry entry for NCT02052310 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,043 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epoetin Alfa is the first listed.
NCT02052310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052310 about?
NCT02052310 is a clinical study titled "Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants". The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants who have just begun dialysis treatment for ESRD.
What is the current status of trial NCT02052310?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,043 participants. The study started on 2014-02-11. Estimated completion is 2018-09-21.
What interventions are being tested in trial NCT02052310?
The interventions under investigation include: Epoetin Alfa (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02052310?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.